## \#\#UOB

## Pillar 3 Disclosure Report

30 June 2017

## Contents

1 INTRODUCTION ..... 2
2 COMPOSITION OF CAPITAL ..... 3
3 Leverage Ratio ..... 10
4 OVERVIEW OF RWA ..... 11
5 CREDIT QUALITY OF Assets ..... 12
6 Changes in Stock of Defaulted Loans and Debt Securities ..... 12
7 SA（CR）AND SA（EQ）－CREDIT RISk Exposure AND CRM Effects ..... 13
8 SA（CR）AND SA（EQ）－Exposures by Asset Classes and Risk Weights ..... 13
9 IRBA－Credit Risk Exposures by Portfolio and PD Range ..... 14
10 IRBA－Effect on RWA of Credit Derivatives used as CRM ..... 18
11 IRBA－Specialised Lending and Equities under the Simple Risk Weight Method ..... 19
12 Analysis of Counterparty Credit Risk Exposure by Approach ..... 20
13 CVA RISK CAPITAL RequIREMENTS ..... 20
14 Standardised Approach－CCR Exposures by Portfolio and Risk Weights ..... 20
15 IRBA－CCR Exposures By Portfolio And PD Range． ..... 21
16 Credit Derivative Exposures ..... 23
17 SECURITISATION ExpOSURES IN THE BANKING BOOK ..... 23
18 Securitisation Exposures in the Banking book and associated Regulatory Capital Requirements －UOB ACTING AS INVESTOR ..... 24
19 MARKET RISK UNDER STANDARDISED APPROACH ..... 25
20 COMPARISON OF VAR Estimates with Gains OR LOSSES ..... 26
21 Banking Book Interest Rate Risk ..... 27
22 Summary of Disclosure Excluded ..... 27
23 AbBREVIATIONS ..... 28

[^0]
## 册UOB

1 INTRODUCTION
UOB Group's Pillar 3 Disclosure Report, prepared in accordance with the Monetary Authority of Singapore ("MAS") Notice to Banks No. 637 "Risk Based Capital Adequacy Requirements for Banks Incorporated in Singapore", comprises mandatory disclosures of the Group's capital composition, leverage ratio and an overview of the Group's risk weighted assets.

The Disclosure Report facilitates an assessment of the Group's capital adequacy and provides an overview of the Group's risk profile. For capital adequacy ratios of the Group's major bank subsidiaries, please refer to the Group Financial Report, available on UOB website www.UOBGroup.com/investor/financial/overview.html.

## 2 Composition of Capital

Tables 1 and $\mathbf{2}$ are mandatory disclosures under the MAS Notice 637 prescribed templates and Basel III transitionary requirements.
Table 1 shows the reconciliation between the Group's published consolidated balance sheet and the regulatory capital components. Details of the regulatory capital components are set out in Table 2, as referenced.
The scope of consolidation for accounting and regulatory purposes is similar, except that subsidiaries which carry out insurance business are not consolidated for regulatory purpose. The list of the Group's major insurance subsidiaries can be found in the Group's Annual Report. As at 30 June 2017, total assets or total equities of each of these subsidiaries were less than $\mathrm{S} \$ 1$ billion.

Table 1 - Reconciliation of Balance Sheet to Regulatory Capital as at $\mathbf{3 0}$ June 2017

| \$m | Balance Sheet per Published Financial Statements | Under regulatory scope of consolidation | Reference in Table 2 |
| :---: | :---: | :---: | :---: |
| Equity |  |  |  |
| Share capital and other capital | 6,805 |  |  |
| of which paid-up ordinary shares | 4,711 | 4,711 | A |
| of which AT1 capital instruments | 2,094 | 2,094 | B |
| Retained earnings | 18,367 | 18,256 | C |
| Other reserves | 9,480 | 9,428 | D |
| Equity attributable to equity holders of the Bank | 34,652 |  |  |
| Non-controlling interests | 178 |  |  |
| of which transitional ineligible surplus NCI of bank subsidiaries |  | 0 | E1 |
| of which NCI that meets criteria for inclusion in |  |  |  |
| - CET1 capital |  | 13 | E2 |
| - AT1 capital |  | 2 | E3 |
| - T2 capital |  | 3 | E4 |
| Total equity | 34,830 |  |  |
| Liabilities |  |  |  |
| Deposits and balances of banks | 11,660 |  |  |
| Deposits and balances of customers | 259,920 |  |  |
| Bills and drafts payable | 796 |  |  |
| Other liabilities | 10,583 |  |  |
| Debts issued | 26,625 |  |  |
| of which transitional ineligible T2 capital instruments | 1,888 | 1,888 | F1 |
| of which T2 capital instruments | 4,269 | 4,269 | F2 |
| Total liabilities | 309,584 |  |  |
| Assets |  |  |  |
| Cash, balances and placements with central banks | 27,387 |  |  |
| Singapore Government treasury bills and securities | 3,527 |  |  |
| Other government treasury bills and securities | 10,290 |  |  |
| Trading securities | 1,741 |  |  |
| Placements and balances with banks | 48,032 |  |  |
| Loans to customers | 223,792 |  |  |
| of which provisions eligible for inclusion in T2 capital |  | 1,111 | G |
| Investment securities ${ }^{1}$ | 11,448 |  |  |
| of which investments in PE/VC held beyond the relevant holding period |  | 24 | H |
| Other assets ${ }^{1}$ | 9,884 |  |  |
| of which amount related to deferred tax assets (net of deferred tax liabilities, where permissible) |  | 298 | I |
| Investment in associates and joint ventures | 1,154 |  |  |
| of which amount related to goodwill |  | 13 | J1 |
| Investment properties | 1,051 |  |  |
| Fixed assets | 1,962 |  |  |
| Intangible assets | 4,147 |  |  |
| of which amount related to goodwill |  | 4,147 | J2 |
| Indirect investments in own capital instruments |  | 0 | K |
| Total Assets | 344,414 |  |  |

[^1]
## 冊UOB

## 2 Composition of Capital (cont'd)

Table 2 lists the regulatory capital components and the corresponding regulatory adjustments.
(a) 'Amount' refers to components of capital calculated in accordance with MAS Notice 637.
(b) 'Amount subject to Pre-Basel III Treatment' refers to components of capital that are computed on Basel III "transitional" rules.
(c) 'Reference in Table 1' links the respective line item to Table 1.

Regulatory adjustments that are deducted against capital are reflected as positive numbers.

Table 2 - Capital Components as at $\mathbf{3 0}$ June 2017

|  | \$m | Amount | Amount subject to Pre-Basel III Treatment | Reference in Table 1 |
| :---: | :---: | :---: | :---: | :---: |
|  | Common Equity Tier 1 capital: instruments and reserves |  |  |  |
| 1 | Paid-up ordinary shares and share premium (if applicable) | 4,711 |  | A |
| 2 | Retained earnings | 18,256 |  | C |
| $3^{\#}$ | Accumulated other comprehensive income and other disclosed reserves | 9,428 |  | D |
| 4 | Directly issued capital subject to phase out from CET1 (only applicable to non-joint stock companies) | - |  |  |
| 5 | Minority interest that meets criteria for inclusion | 13 | (0) | E1+E2, -E1 |
| 6 | Common Equity Tier 1 capital before regulatory adjustments | 32,407 |  |  |
|  | Common Equity Tier 1 capital: regulatory adjustments |  |  |  |
| 7 | Valuation adjustment pursuant to Part VIII of MAS Notice 637 | - |  |  |
| 8 | Goodwill, net of associated deferred tax liability | 3,327 | 832 | J1+J2 |
| $9{ }^{\text {\# }}$ | Intangible assets, net of associated deferred tax liability | - | - |  |
| 10* | Deferred tax assets that rely on future profitability | 239 | 60 | I |
| 11 | Cash flow hedge reserve | - | - |  |
| 12 | Shortfall of TEP relative to EL under IRBA | - | - |  |
| 13 | Increase in equity capital resulting from securitisation transactions | - | - |  |
| 14 | Unrealised fair value gains/losses on financial liabilities and derivative liabilities arising from changes in own credit risk | - | - |  |
| 15 | Defined benefit pension fund assets, net of associated deferred tax liability | - |  |  |
| 16 | Investments in own shares | 0 |  | K |
| 17 | Reciprocal cross-holdings in ordinary shares of financial institutions | - |  |  |
| 18 | Investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank does not hold a major stake | - |  |  |
| 19 | Investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries) (amount above 10\% threshold) | - | - |  |
| $20^{\text {\# }}$ | Mortgage servicing rights (amount above 10\% threshold) | - |  |  |
| $21^{\text {\# }}$ | Deferred tax assets arising from temporary differences (amount above 10\% threshold, net of related tax liability) | - |  |  |
| 22 | Amount exceeding the 15\% threshold | - |  |  |
| 23 | of which investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries) | - |  |  |
| $24^{\#}$ | of which mortgage servicing rights | - |  |  |
| $25^{\#}$ | of which deferred tax assets arising from temporary differences | - |  |  |
| 26 | National specific regulatory adjustments | 20 |  |  |
| 26A | PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630 | 20 | 5 | H |
| 26B | Capital deficits in subsidiaries and associates that are regulated financial institutions | - | - |  |
| 26C | Any other items which the Authority may specify | - |  |  |
| 27 | Regulatory adjustments applied in calculation of CET1 Capital due to insufficient AT1 Capital to satisfy required deductions | - |  |  |
| 28 | Total regulatory adjustments to CET1 Capital | 3,586 |  |  |
| 29 | Common Equity Tier 1 capital (CET1) | 28,821 |  |  |
|  | Additional Tier 1 capital: instruments |  |  |  |
| 30 | AT1 capital instruments and share premium (if applicable) | 2,094 |  | B |
| 31 | of which classified as equity under the Accounting Standards | 2,094 |  |  |
| 32 | of which classified as liabilities under the Accounting Standards | - |  |  |
| 33 | Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4) | - |  |  |
| 34 | AT1 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion | 2 |  | E3 |
| 35 | of which instruments issued by subsidiaries subject to phase out | - |  |  |
| 36 | Additional Tier 1 capital before regulatory adjustments | 2,096 |  |  |
|  | Additional Tier 1 capital: regulatory adjustments |  |  |  |
| 37 | Investments in own AT1 capital instruments | - |  |  |

Table 2 - Capital Components as at 30 June 2017

|  | \$m | Amount | Amount subject to Pre-Basel III Treatment | Reference in Table 1 |
| :---: | :---: | :---: | :---: | :---: |
| 38 | Reciprocal cross-holdings in AT1 capital instruments of financial institutions | - |  |  |
| 39 | Investments in AT1 capital instruments of unconsolidated financial institutions in which Reporting Bank does not hold a major stake | - |  |  |
| 40 | Investments in AT1 capital instruments of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries) | - | - |  |
| 41 | National specific regulatory adjustments | 891 |  |  |
| 41A | Regulatory adjustments applied to AT1 Capital in respect of amounts subject to pre-Basel III treatment | 891 |  |  |
|  | of which goodwill, net of associated deferred tax liability | 832 |  | row 8 at 20\% |
|  | of which intangible assets, net of associated deferred tax liability | - |  |  |
|  | of which deferred tax assets that rely on future profitability | 60 |  | row 10 at 20\% |
|  | of which cash flow hedge reserve | - |  |  |
|  | of which increase in equity capital resulting from securitisation transactions | - |  |  |
|  | of which unrealised fair value gains/losses on financial liabilities and derivative liabilities arising from changes in own credit risk | - |  |  |
|  | of which shortfall of TEP relative to EL under IRBA | - |  |  |
|  | of which PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630 | - |  |  |
|  | of which capital deficits in subsidiaries and associates that are regulated financial institutions | - |  |  |
|  | of which investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (incl insurance subsidiaries) | - |  |  |
|  | of which investments in Tier 2 capital instruments of unconsolidated financial institutions in which the Reporting Bank holds a major stake (incl insurance subsidiaries) | - |  |  |
| 41B | Any other items which the Authority may specify | - |  |  |
| 42 | Regulatory adjustments applied in calculation of AT1 Capital due to insufficient Tier 2 Capital to satisfy required deductions | - |  |  |
| 43 | Total regulatory adjustments to Additional Tier 1 capital | 891 |  |  |
| 44 | Additional Tier 1 capital (AT1) | 1,205 |  |  |
| 45 | Tier 1 capital (T1 = CET1 + AT1) | 30,026 |  |  |
|  | Tier 2 capital: instruments and provisions |  |  |  |
| 46 | Tier 2 capital instruments and share premium (if applicable) | 4,269 |  | F2 |
| 47 | Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4) | 1,888 |  | F1 |
| 48 | Tier 2 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion | 3 |  | E4 |
| 49 | of which instruments issued by subsidiaries subject to phase out | - |  |  |
| 50 | Provisions | 1,111 |  | G |
| 51 | Tier 2 capital before regulatory adjustments | 7,271 |  |  |
|  | Tier 2 capital: regulatory adjustments |  |  |  |
| 52 | Investments in own Tier 2 instruments | 0 |  | K |
| 53 | Reciprocal cross-holdings in Tier 2 capital instruments of financial institutions | - |  |  |
| 54 | Investments in Tier 2 capital instruments of unconsolidated financial institutions in which the Reporting Bank does not hold a major stake | - |  |  |
| 55 | Investments in Tier 2 capital instruments of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries) | - | - |  |
| 56 | National specific regulatory adjustments | 5 |  |  |
| 56A | Any other items which the Authority may specify | - |  |  |
| 56B | Regulatory adjustments applied to Tier 2 Capital in respect of amounts subject to pre-Basel III treatment | 5 |  |  |
|  | of which shortfall of TEP relative to EL under IRBA | - |  |  |
|  | of which PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630 | 5 |  | row 26A at 20\% |
|  | of which capital deficits in subsidiaries and associates that are regulated financial institutions | - |  |  |
|  | of which investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (incl insurance subsidiaries) | - |  |  |
|  | of which investments in AT1 capital instruments of unconsolidated financial institutions in which the Reporting Bank holds a major stake (incl insurance subsidiaries) | - |  |  |
| 57 | Total regulatory adjustments to Tier 2 capital | 5 |  |  |
| 58 | Tier 2 capital (T2) | 7,266 |  |  |

## 2 COMPOSITION OF CAPITAL (cont'd)

Table 2 - Capital Components as at 30 June 2017

|  | \$m | Amount | Amount subject to Pre-Basel III Treatment | Reference in Table 1 |
| :---: | :---: | :---: | :---: | :---: |
| 59 | Total capital (TC = T1 + T2) | 37,292 |  |  |
| 60 | Floor-adjusted total risk weighted assets (after incorporating the floor adjustment) | 209,276 |  |  |
|  | Capital ratios (as a percentage of floor-adjusted risk weighted assets) |  |  |  |
| 61 | Common Equity Tier 1 CAR | 13.8\% |  |  |
| 62 | Tier 1 CAR | 14.3\% |  |  |
| 63 | Total CAR | 17.8\% |  |  |
| 64 | Bank-specific buffer requirement | 7.841\% |  |  |
| 65 | of which capital conservation buffer requirement | 1.250\% |  |  |
| 66 | of which bank specific countercyclical buffer requirement ${ }^{1}$ | 0.091\% |  |  |
| 67 | of which G-SIB buffer requirement (if applicable) | - |  |  |
| 68 | Common Equity Tier 1 available to meet buffers | 6.3\% |  |  |
|  | National minima |  |  |  |
| 69 | Minimum CET1 CAR | 6.5\% |  |  |
| 70 | Minimum Tier 1 CAR | 8.0\% |  |  |
| 71 | Minimum Total CAR | 10.0\% |  |  |
|  | Amounts below the thresholds for deduction (before risk weighting) |  |  |  |
| 72 | Investments in ordinary shares, AT1 capital and Tier 2 capital of unconsolidated financial institutions in which the bank does not hold a major stake | 275 |  |  |
| 73 | Investments in ordinary shares of unconsolidated financial institutions in which the Reporting Bank holds a major stake (including insurance subsidiaries) | 2,292 |  |  |
| 74 | Mortgage servicing rights (net of related tax liability) | - |  |  |
| 75 | Deferred tax assets arising from temporary differences (net of related tax liability) | - |  |  |
|  | Applicable caps on the inclusion of provisions in Tier 2 |  |  |  |
| 76 | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to standardised approach (prior to application of cap) | 349 |  |  |
| 77 | Cap on inclusion of provisions in Tier 2 under standardised approach | 281 |  | row 50 |
| 78 | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to internal ratings-based approach (prior to application of cap) | 995 |  |  |
| 79 | Cap for inclusion of provisions in Tier 2 under internal ratings-based approach | 830 |  | row 50 |
|  | Capital instruments subject to phase-out arrangements (only applicable between 1 Jan 2013 and 1 Jan 2022) |  |  |  |
| 80 | Current cap on CET1 instruments subject to phase out arrangements | - |  |  |
| 81 | Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities) | - |  |  |
| 82 | Current cap on AT1 instruments subject to phase out arrangements | 1,074 |  |  |
| 83 | Amount excluded from AT1 due to cap (excess over cap after redemptions and maturities) | - |  |  |
| 84 | Current cap on T2 instruments subject to phase out arrangements | 2,607 |  |  |
| 85 | Amount excluded from T2 due to cap (excess over cap after redemptions and maturities) | - |  |  |

[^2]Note:
1 The Group's countercyclical buffer (CCyB) is computed as the weighted average of effective CCyB in jurisdictions where the Group has private sector exposures. As at 30 Jun 2017, the Group has private sector exposures to Hong Kong and Sweden, where the effective country-specific CCyB was $1.25 \%$ for the year of 2017. The weights applied to Hong Kong and Sweden exposures are 7\% and $0 \%$ respectively.

## 2 COMPOSITION OF CAPITAL (cont'd)

## Key Features of Capital Instruments as at 30 June 2017

## Issuer

Unique Identifier (ISIN code)
Governing law(s) of the instrument
Regulatory treatment
Transitional Basel III rules
Post-transitional Basel III rules
Eligible at solo/group/group\&solo
Instrument type
Amount recognised in regulatory capital (in millions)
Principal amount (in millions)
Accounting classification
Original date of issuance
Perpetual or dated
Original maturity date
Issuer call subject to prior supervisory approval
Optional call date
Tax/ regulatory event call
Redemption price
16 Subsequent call dates, if applicable

## Coupons / dividends

17 Fixed or floating ${ }^{(1)}$
18 Coupon rate and any related index

19 Existence of a dividend stopper
Fully discretionary, discretionally or mandatory
Existence of step up or incentive to redeem
Existence of step up or incentive
Non-cumulative or cumulative
Convertible or non-convertible
If convertible, conversion trigger
If convertible, fully or partially
If convertible, conversion rate
If convertible, mandatory or optional conversion
If convertible, specify instrument type convertible into
If convertible, specify issuer of instrument it converts into
Write-down feature
If write-down, write-down triggers(s)
If write-down, full or partial
If write-down, permanent or temporary
If temporary write-down, description of write-up mechanism Position in subordination hierarchy in liquidation (instrument type immediately senior to instrument)
36 Non compliant transitioned features
37 If yes, specify non compliant features


| United Overseas Bank Limited | United Overseas Bank Limited | United Overseas Bank Limited |
| :---: | :---: | :---: |
| SG72C9000002 | SG5817998534 | SG57A1994579 |
| Singapore | Singapore | Singapore |


| Core Equity |
| :---: |
| Core Equity |
| Group \& Solo |
| Ordinary Share |
| $\mathbf{S} \$ 4,711$ million |
| n.a. |
| Equity |
| 20 July 1970 |
| Perpetual |
| No maturity |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |


| Additional Tier 1 | Additional Tier 1 | Additional Tier 1 |
| :---: | :---: | :---: |
| Additional Tier 1 | Additional Tier 1 | Additional Tier 1 |
| Group \& Solo | Group \& Solo | Group \& Solo |
| Perpetual Capital Security | Perpetual Capital Security | Perpetual Capital Security |
| $\mathrm{S} \$ 748$ million | $\mathrm{S} \$ 499$ million | $\mathrm{S} \$ 847$ million |
| $\mathrm{S} \$ 750$ million | $\mathrm{S} \$ 500$ million | $\mathrm{S} \$ 850$ million |
| Equity | Equity | Equity |
| 18 May 2016 | 19 November 2013 | 23 July 2013 |
| Perpetual | Perpetual | Perpetual |
| No maturity | No maturity | No maturity |
| Yes | Yes | Yes |
| 18 May 2021 | 19 November 2019 | Yes |
| Yes | Par | Yes |
| Par | Par | Par |
| Each distribution payment date <br> thereafter | Each distribution payment date <br> thereafter | Each distribution payment date |
| thereafter |  |  |


| Discretionary dividend amount |
| :---: |
| n.a. |
| n.a. |
| Fully discretionary |
| n.a. |
| Non-cumulative |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| n.a. |
| Additional Tier 1 instruments |
| No. |
| n.a. |
| (1) Detais ne.fix |


| Fixed | Fixed | Fixed |
| :---: | :---: | :---: |
| 4.00\% paid semi-annually on 18 May \& 18 November | 4.75\% paid semi-annually on 19 May \& 19 November | 4.90\% paid semi-annually on 23 January \& 23 July |
| Yes | Yes | Yes |
| Fully discretionary | Fully discretionary | Fully discretionary |
| No | No | No |
| Non-cumulative | Non-cumulative | Non-cumulative |
| Non-convertible | Non-convertible | Non-convertible |
| n.a. | n.a. | n.a. |
| n.a. | n.a. | n.a. |
| n.a. | n.a. | n.a. |
| n.a. | n.a. | n.a. |
| n.a. | n.a. | n.a. |
| n.a. | n.a. | n.a. |
| Yes | Yes | Yes |
| Point of non-viability at the discretion of the Regulator | Point of non-viability at the discretion of the Regulator | Point of non-viability at the discretion of the Regulator |
| Partial | Partial | Partial |
| Permanent | Permanent | Permanent |
| n.a. | n.a. | n.a. |
| Tier 2 instruments | Tier 2 instruments | Tier 2 instruments |
| No | No | No |
| n.a. | n.a. | n.a. |

(1) Details on re-fixing of the dividend/interest rate on the first call date are available in the UOB website.

## 冊UOB

## 2 COMPOSITION OF CAPITAL（cont＇d）

## Key Features of Capital Instruments as at 30 June 2017

## Issuer

Unique Identifier（ISIN code）
Governing law（s）of the instrument

## latory treatment

Transitional Basel III rules
Post－transitional Basel III rules
Eligible at solo／group／group\＆solo
Instrument type
Amount recognised in regulatory capital（in millions）
Principal amount（in millions）
Accounting classification
Original date of issuance
Perpetual or dated
Original maturity dat
Issuer call subject to prior supervisory approval Optional call date
Tax／regulatory event call
Redemption price
16 Subsequent call dates，if applicable

## Coupons／dividends

Fixed or floating ${ }^{(1)}$
Coupon rate and any related index

Existence of a dividend stopper
Fully discretionary，discretionally or mandatory
Existence of step up or incentive to redeem
Non－cumulative or cumulative
Convertible or non－convertible
If convertible，conversion trigger
If convertible，fully or partially
If convertible，conversion rate
If convertible，mandatory or optional conversion
If convertible，specify instrument type convertible into
If convertible，specify issuer of instrument it converts into
Write－down feature
If write－down，write－down triggers（s）
If write－down，full or partial
If write－down，permanent or temporary
If temporary write－down，description of write－up mechanism Position in subordination hierarchy in liquidation（instrument type immediately senior to instrument）
36 Non compliant transitioned features
37 If yes，specify non compliant features

| United Overseas Bank Limited | United Overseas Bank Limited | United Overseas Bank Limited | United Overseas Bank Limited |
| :---: | :---: | :---: | :---: |
| SG79A8000002 | XS1485603408 | XS1480822516 | XS1379133058 |
| Singapore | Singapore | Singapore | Singapore |
| Tier 2 | Tier 2 | Tier 2 | Tier 2 |
| Tier 2 | Tier 2 | Tier 2 | Tier 2 |
| Group \＆Solo | Group \＆Solo | Group \＆Solo | Group \＆Solo |
| Subordinated Debt | Subordinated Debt | Subordinated Debt | Subordinated Debt |
| S\＄763 million | S\＄826 million | S\＄119 million | S\＄951 million |
| S\＄750 million | US\＄600 million | HK\＄700 million | US $\$ 700$ million ${ }^{(2)}$ |
| Liability | Liability | Liability | Liability |
| 27 February 2017 | 8 September 2016 | 26 August 2016 | 16 \＆ 24 March 2016 |
| Dated | Dated | Dated | Dated |
| 27 February 2029 | 8 March 2027 | 26 August 2028 | 16 September 2026 |
| Yes | Yes | Yes | Yes |
| 27 February 2024 | 8 March 2022 | 26 August 2023 | 16 September 2021 |
| Yes | Yes | Yes | Yes |
| Par | Par | Par | Par |
| Not applicable．One time call only． | Not applicable．One time call only． | Not applicable．One time call only． | Not applicable．One time call only． |
|  |  |  |  |
| Fixed | Fixed | Fixed | Fixed |
| 3．50\％paid semi－annually on 27 February and 27 August | 2．88\％paid semi－annually on 8 March and 8 September | 3．19\％paid quarterly on 26 August， 26 November， 26 February and 26 May | 3．5\％paid semi－annually on 16 March and 16 September |
| No | No | No | No |
| Mandatory | Mandatory | Mandatory | Mandatory |
| No | No | No | No |
| Cumulative | Cumulative | Cumulative | Cumulative |
| Non－convertible | Non－convertible | Non－convertible | Non－convertible |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| Yes | Yes | Yes | Yes |
| Point of non－viability at the discretion of the Regulator | Point of non－viability at the discretion of the Regulator | Point of non－viability at the discretion of the Regulator | Point of non－viability at the discretion of the Regulator |
| Partial | Partial | Partial | Partial |
| Permanent | Permanent | Permanent | Permanent |
| n．a． | n．a． | n．a． | n．a． |
| Unsubordinated and unsecured obligations | Unsubordinated and unsecured obligations | Unsubordinated and unsecured obligations | Unsubordinated and unsecured obligations |
| No | No | No | No |
| n．a． | n．a． | n．a． | n．a． |

which was consolidated and formed a single series with the US $\$ 500 \mathrm{~m}$ tranche issued on 16 March 2016.

## \＃UOB

## 2 COMPOSITION OF CAPITAL（cont＇d）

Key Features of Capital Instruments as at 30 June 2017

1 Issuer
2 Unique Identifier（ISIN code）
Governing law（s）of the instrument
Regulatory treatment
Transitional Basel III rules
Post－transitional Basel III rules
Eligible at solo／group／group\＆solo
Instrument type
Amount recognised in regulatory capital（in millions）
Principal amount（in millions）
Accounting classification
Original date of issuance
Perpetual or dated
Original maturity date
Issuer call subject to prior supervisory approval
Optional call date
event call
Redemption price
16 Subsequent call dates，if applicable
Coupons／dividends
17 Fixed or floating ${ }^{(1)}$
18 Coupon rate and any related index

Existence of a dividend stopper
Fully discretionary，discretionally or mandatory
Existence of step up or incentive to redeem
Non－cumulative or cumulative
Convertible or non－convertible
If convertible，conversion trigger
If convertible，fully or partially
If convertible，conversion rate
If convertible，mandatory or optional conversion
If convertible，specify instrument type convertible into
If convertible，specify issuer of instrument it converts into
Write－down feature
If write－down，write－down triggers（s）
If write－down，full or partial
If write－down，permanent or temporary
If temporary write－down，description of write－up mechanism
Position in subordination hierarchy in liquidation（instrument type immediam senior to instrument）
36 N
37 If yes，specify non compliant features

| United Overseas Bank Limited | United Overseas Bank Limited | United Overseas Bank Limited | United Overseas Bank Limited |
| :---: | :---: | :---: | :---: |
| SG6QD3000002 | XS1045409965 | SG6V61983429 | XS0843128603 |
| Singapore | Singapore | Singapore | Singapore |
| Tier 2 | Tier 2 | Tier 2 | Tier 2 |
| Tier 2 | Tier 2 | Ineligible | Ineligible |
| Group \＆Solo | Group \＆Solo | Group \＆Solo | Group \＆Solo |
| Subordinated Debt | Subordinated Debt | Subordinated Debt | Subordinated Debt |
| S\＄505 million | S $\$ 1,105$ million | S $\$ 1,200$ million | S\＄688 million |
| S\＄500 million | US\＄800 million | S\＄1，200 million | US\＄500 million |
| Liability | Liability | Liability | Liability |
| 22 May 2014 | 19 March 2014 | 11 July 2012 | 17 October 2012 |
| Dated | Dated | Dated | Dated |
| 22 May 2026 | 19 September 2024 | 11 July 2022 | 17 October 2022 |
| Yes | Yes | Yes | Yes |
| 22 May 2020 | 19 September 2019 | 11 July 2017 | 17 October 2017 |
| Yes | Yes | Yes | Yes |
| Par | Par | Par | Par |
| Not applicable．One time call only． | Not applicable．One time call only． | Each interest payment date thereafter | Each interest payment date thereafter |
|  |  |  |  |
| Fixed | Fixed | Fixed | Fixed |
| $3.5 \%$ paid semi－annually on 22 May and 22 November | $3.75 \%$ paid semi－annually on 19 March and 19 September | $3.15 \%$ paid semi－annually on 11 January and 11 July | 2．875\％paid semi－annually on 17 April and 17 October |
| No | No | No | No |
| Mandatory | Mandatory | Mandatory | Mandatory |
| No | No | No | No |
| Cumulative | Cumulative | Cumulative | Cumulative |
| Non－convertible | Non－convertible | Non－convertible | Non－convertible |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| Yes | Yes | No | No |
| Point of non－viability at the discretion of the Regulator | Point of non－viability at the discretion of the Regulator | n．a． | n．a． |
| Partial | Partial | n．a． | n．a． |
| Permanent | Permanent | n．a． | n．a． |
| n．a． | n．a． | n．a． | n．a． |
| Unsubordinated and unsecured obligations | Unsubordinated and unsecured obligations | Unsubordinated and unsecured obligations | Unsubordinated and unsecured obligations |
| No | No | Yes | Yes |
| n．a． | n．a． | No loss absorption features | No loss absorption features |

## 冊 UOB

## 3 Leverage Ratio

The Basel III framework introduced Leverage Ratio as a non-risk-based backstop limit to supplement the risk-based capital requirements. It aims to constrain the build-up of excess leverage in the banking sector, with additional safeguards against model risk and measurement errors.

Leverage Ratio is expressed as Tier 1 Capital against Exposure Measure, which comprises on- and off-balance sheet items.

| $\$ \mathrm{~m}$ | 30 Jun 2017 | 31 Mar 2017 | 31 Dec 2016 | 30 Sep 2016 |
| :--- | ---: | ---: | ---: | ---: |
| Tier 1 capital | $\mathbf{3 0 , 0 2 6}$ | 29,131 | 28,280 | 27,768 |
| Exposure measure | $\mathbf{3 8 5 , 8 1 6}$ | 384,439 | 380,238 |  |
| Leverage ratio | $\mathbf{7 . 8 \%}$ | $7.6 \%$ | $\mathbf{3 6 7 , 8 4 8}$ |  |

Disclosure of Leverage Ratio is presented in prescribed templates under MAS Notice 637.
Table 1 shows the reconciliation between the Group's published balance sheet assets and the Exposure Measure.
Table 2 sets out the components of Exposure Measure.

Table 1 - Reconciliation of Balance Sheet Assets to Exposure Measure as at 30 Jun 2017

|  | $\$ \mathbf{m}$ | Amount  <br> 1 Total consolidated assets as per published financial statements <br> 2 Adjustment for investments in entities that are consolidated for accounting purposes but are outside the regulatory scope <br> of consolidation <br> 3 Adjustment for fiduciary assets recognised on the balance sheet in accordance with the Accounting Standards but <br> excluded from the calculation of the exposure measure <br> 4 Adjustment for derivative transactions <br> 5 Adjustment for SFTs <br> 6 Adjustment for off-balance sheet items <br> 7 Other adjustments <br> 8 Exposure measure |
| ---: | :--- | ---: |

Table 2 - Exposure Measure Components as at 30 Jun 2017

|  | \$m | Amount |
| :---: | :---: | :---: |
|  | Exposure measures of on-balance sheet items |  |
| 1 | On-balance sheet items (excluding derivative transactions and SFTs, but including on-balance sheet collateral for derivative transactions or SFTs) | 328,693 |
| 2 | Asset amounts deducted in determining Tier 1 capital | $(4,477)$ |
| 3 | Total exposure measures of on-balance sheet items (excluding derivative transactions and SFTs) | 324,216 |
|  | Derivative exposure measures |  |
| 4 | Replacement cost associated with all derivative transactions (net of the eligible cash portion of variation margins) | 4,080 |
| 5 | Potential future exposure associated with all derivative transactions | 5,689 |
| 6 | Gross-up for derivative collaterals provided where deducted from the balance sheet assets in accordance with the Accounting Standards | - |
| 7 | Deductions of receivables for the cash portion of variation margins provided in derivative transactions | - |
| 8 | CCP leg of trade exposures excluded | - |
| 9 | Adjusted effective notional amount of written credit derivatives | 237 |
| 10 | Further adjustments in effective notional amounts and deductions from potential future exposures of written credit derivatives | - |
| 11 | Total derivative exposure measures | 10,006 |
|  | SFT exposure measures |  |
| 12 | Gross SFT assets (with no recognition of accounting netting), after adjusting for sales accounting | 9,653 |
| 13 | Eligible netting of cash payables and cash receivables | - |
| 14 | SFT counterparty exposures | 206 |
| 15 | SFT exposure measures where a Reporting Bank acts as an agent in the SFTs | - |
| 16 | Total SFT exposure measures | 9,860 |
|  | Exposure measures of off-balance sheet items |  |
| 17 | Off-balance sheet items at notional amount | 179,416 |
| 18 | Adjustments for calculation of exposure measures of off-balance sheet items | $(137,682)$ |
| 19 | Total exposure measures of off-balance sheet items | 41,734 |
|  | Capital and Total exposures |  |
| 20 | Tier 1 capital | 30,026 |
| 21 | Total exposures | 385,816 |
|  | Leverage ratio |  |
| 22 | Leverage ratio | 7.8\% |

The table below lists the Group's RWA by risk type and approach, as prescribed under MAS Notice 637. The minimum capital requirement is stated at $10.0 \%$ of RWA.

The Group's RWA comprises credit RWA (84.2\%), market RWA (9.3\%), and operational RWA (6.5\%).
Total RWA at 30 June 2017 remains stable at $\$ 209.3$ billion.

| \$m |  | (a) | (b) | (c) |
| :---: | :---: | :---: | :---: | :---: |
|  |  | RWA |  | Minimum capital |
|  |  | $\begin{array}{r} \text { As at } \\ 30 \text { Jun } 2017 \end{array}$ | $\begin{array}{r} \text { As at } \\ 31 \text { Mar } 2017 \end{array}$ | $\begin{array}{r} \text { As at } \\ 30 \text { Jun } 2017 \end{array}$ |
| 1 | Credit risk (excluding CCR) | 158,161 | 159,677 | 15,816 |
| 2 | of which $\operatorname{SA}(C R)$ and $\operatorname{SA}(E Q)$ | 21,269 | 21,166 | 2,127 |
| 3 | of which IRBA and IRBA(EQ) for equity exposures under the PD/LGD method | 136,892 | 138,510 | 13,689 |
| 4 | CCR | 4,388 | 5,528 | 439 |
| 5 | of which Current Exposure Method | 2,531 | 2,754 | 253 |
| 6 | of which CCR Internal Models Method | - | - | - |
| 7 | IRBA(EQ) for equity exposures under the simple risk weight method or the IMM | 4,636 | 4,566 | 464 |
| 8 | Equity investments in funds - look through approach | 277 | 252 | 28 |
| 9 | Equity investments in funds - mandate-based approach | 2,927 | 2,990 | 293 |
| 10 | Equity investments in funds - fall back approach | 14 | 14 | 1 |
| 10a | Equity investment in funds - partial use of an approach | - | - | - |
| 11 | Unsettled transactions | - | - | - |
| 12 | Securitisation exposures in the banking book | 176 | 179 | 18 |
| 13 | of which IRBA(SE) - RBM and IAM | 176 | 179 | 18 |
| 14 | of which IRBA(SE) - SF | - | - | - |
| 15 | of which SA(SE) | - | - | - |
| 16 | Market risk | 19,371 | 19,026 | 1,937 |
| 17 | of which SA(MR) | 19,371 | 19,026 | 1,937 |
| 18 | of which IMA | - | - | - |
| 19 | Operational risk | 13,594 | 13,417 | 1,359 |
| 20 | of which BIA | - | - | - |
| 21 | of which SA(OR) | 13,594 | 13,417 | 1,359 |
| 22 | of which AMA | - | - | - |
| 23 | Amounts below the thresholds for deduction (subject to 250\% risk weight) | 5,730 | 5,490 | 573 |
| 24 | Floor adjustment | - | - | - |
| 25 | Total | 209,276 | 211,139 | 20,928 |

## 5 Credit Quality of Assets

A default on the obligor is considered to have occurred when either or both of the followings have taken place：
－The obligor is unlikely to pay its credit obligations to the Group in full，without recourse by the bank to actions such as realising security（if held）．
－The obligor is past due more than 90 days on any credit obligation to the Group．Overdrafts will be considered as being past due once the outstanding has breached an advised limit．


## 6 Changes in Stock of Defaulted Loans and Debt Securities

| $\$ \mathbf{~}$ | （a） |  |
| ---: | :--- | ---: |
| $\mathbf{1}$ | Defaulted loans and debt securities at end of the previous semi－annual reporting period | 3,385 |
| 2 | Loans and debt securities that have defaulted since the previous semi－annual reporting period | 864 |
| $\mathbf{3}$ | Returned to non－defaulted status | $(118)$ |
| 4 | Amounts written－off | $(290)$ |
| 5 | Other changes | $(319)$ |
| $\mathbf{6}$ | Defaulted loans and debt securities at end of the semi－annual reporting period $\mathbf{( 1 + 2 + 3 + 4 + / - 5 )}$ | $\mathbf{3 , 5 2 2}$ |


|  |  | （a） | （b） | （c） | （d） | （e） | （f） |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Exposures before CCF and CRM |  | Exposures post－CCF and post－CRM |  | RWA and RWA density |  |
|  | Asset classes and others | On－balance sheet amount \＄m | Off－balance sheet amount \＄m | On－balance sheet amount \＄m | Off－balance sheet amount \＄m | $\begin{array}{r} \text { RWA } \\ \text { \$m } \end{array}$ | RWA density |
| 1 | Cash items | 2，854 | 321 | 2，854 | 321 | 20 | 1 |
| 2 | Central government and central bank | 1，668 | － | 1，668 | － | 171 | 10 |
| 3 | PSE | 1，070 | 627 | 1，070 | － | 72 | 7 |
| 4 | MDB | 356 | 0 | 691 | － | 124 | 18 |
| 5 | Bank | 721 | 289 | 757 | 31 | 424 | 54 |
| 6 | Corporate | 9，186 | 17，001 | 7，999 | 1，560 | 9，366 | 98 |
| 7 | Regulatory retail | 1，503 | 1，464 | 1，270 | 26 | 972 | 75 |
| 8 | Residential mortgage | 1，887 | 9 | 1，887 | － | 803 | 43 |
| 9 | CRE | 2，268 | 1，032 | 2，250 | 87 | 2，337 | 100 |
| 10 | Equity－SA（EQ） | － | － | － | － | － | － |
| 11 | Past due exposures | 263 | 7 | 263 | 0 | 358 | 136 |
| 12 | Higher－risk categories | － | － | － | － | － | － |
| 13 | Other exposures | 7，753 | 906 | 6，493 | 129 | 6，622 | 100 |
| 14 | Total | 29，528 | 21，656 | 27，202 | 2，153 | 21，269 | 72 |

## 8 SA（CR）and SA（EQ）－Exposures by Asset Classes and Risk Weights

| \＄m |  | （a） | （b） | （c） | （d） | （e） | （f） | （g） | （h） | （i） | （j） |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 0\％ | 10\％ | 20\％ | 35\％ | 50\％ | 75\％ | 100\％ | 150\％ | Others | Total credit exposure amount （post－CCF and post－CRM） |
| 1 | Cash items | 3，073 | － | 102 | － | － | － | － | － | － | 3，175 |
| 2 | Central government and central bank | 1，325 | － | － | － | 343 | － | － | － | － | 1，668 |
| 3 | PSE | 941 | － | － | － | 114 | － | 15 | － | － | 1，070 |
| 4 | MDB | 444 | － | － | － | 247 | － | － | － | － | 691 |
| 5 | Bank | － | － | 144 | － | 497 | － | 147 | － | － | 788 |
| 6 | Corporate | － | － | 185 | － | 90 | － | 9，284 | － | － | 9，559 |
| 7 | Regulatory retail | － | － | － | － | － | 1，296 | － | － | － | 1，296 |
| 8 | Residential mortgage | － | － | － | 1，662 | － | 13 | 211 | － | － | 1，887 |
| 9 | CRE | － | － | － | － | － | － | 2，337 | － | － | 2，337 |
| 10 | Equity－SA（EQ） | － | － | － | － | － | － | － | － | － | － |
| 11 | Past due exposures | － | － | － | － | － | － | 73 | 190 | － | 263 |
| 12 | Higher－risk categories | － | － | － | － | － | － | － | － | － | － |
| 13 | Other exposures | － | － | － | － | － | － | 6，622 | － | － | 6，622 |
| 14 | Total | 5，783 | － | 431 | 1，662 | 1，291 | 1，309 | 18，689 | 190 | － | 29，355 |

## 冊UOB

9 IRBA - CREDIt RISK ExpOSURES BY Portfolio and PD Range

|  | (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | (k) | (I) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PD range | $\begin{array}{r} \hline \text { Original } \\ \text { on- } \\ \text { balance } \\ \text { sheet } \\ \text { gross } \\ \text { exposures } \\ \$ \mathrm{~m} \\ \hline \end{array}$ | Off- <br> balance sheet <br> exposures <br> pre-CCF <br> $\$ \mathrm{~m}$ | Average CCF \% | EAD post-CRM and post-CCF $\$ \mathrm{~m}$ | Average PD $\%$ | Number of Obligors | Average LGD $\%$ | Average Maturity Years | $\begin{array}{r} \text { RWA } \\ \$ \mathrm{~m} \\ \hline \end{array}$ | RWA density $\%$ | $\begin{aligned} & \text { EL } \\ & \$ \mathrm{~m} \end{aligned}$ | $\begin{array}{r} \text { TEP } \\ \$ \mathrm{~m} \\ \hline \end{array}$ |
| Sovereign asset sub-class |  |  |  |  |  |  |  |  |  |  |  |  |
| 0.00 to < 0.15 | 30,213 | 252 | 93 | 30,707 | 0.0 | 24 | 45 | 1.3 | 1,098 | 4 | 1 |  |
| 0.15 to $<0.25$ | 58 | - | - | 58 | 0.2 | 1 | 45 | 1.0 | 20 | 34 | 0 |  |
| 0.25 to $<0.50$ | 85 | - | - | 85 | 0.4 | 2 | 45 | 1.0 | 38 | 45 | 0 |  |
| 0.50 to $<0.75$ | - | - | - | - | - | - | - | - | - | - | - |  |
| 0.75 to <2.50 | 60 | - | - | 60 | 1.5 | 2 | 45 | 1.1 | 56 | 94 | 0 |  |
| 2.50 to < 10.00 | - | - | - | - | - | - | - | - | - | - | - |  |
| 10.00 to <100.00 | 62 | - | - | 62 | 18.5 | 1 | 45 | 1.0 | 144 | 232 | 5 |  |
| 100.00 (Default) | - | - | - | - | - | - | - | - | - | - | - |  |
| Sub-total | 30,478 | 252 | 93 | 30,972 | 0.1 | 30 | 45 | 1.3 | 1,356 | 4 | 7 | 21 |
| Bank asset sub-class |  |  |  |  |  |  |  |  |  |  |  |  |
| 0.00 to < 0.15 | 30,630 | 4,191 | 42 | 32,550 | 0.1 | 150 | 45 | 0.5 | 4,020 | 12 | 8 |  |
| 0.15 to $<0.25$ | 2,778 | 192 | 79 | 2,967 | 0.2 | 24 | 45 | 0.7 | 1,065 | 36 | 3 |  |
| 0.25 to $<0.50$ | 2,832 | 244 | 74 | 3,012 | 0.4 | 18 | 45 | 0.6 | 1,513 | 50 | 5 |  |
| 0.50 to $<0.75$ | 2,246 | 11 | 100 | 2,258 | 0.6 | 14 | 45 | 0.1 | 1,227 | 54 | 6 |  |
| 0.75 to < 2.50 | 254 | 69 | 99 | 325 | 1.2 | 16 | 45 | 0.1 | 225 | 69 | 2 |  |
| 2.50 to < 10.00 | 331 | 12 | 100 | 61 | 4.3 | 14 | 38 | 0.3 | 62 | 101 | 1 |  |
| 10.00 to <100.00 | 126 | 41 | 13 | 79 | 18.6 | 17 | 45 | 0.4 | 176 | 224 | 7 |  |
| 100.00 (Default) | - | - | - | - | - | - | - | - | - | - | - |  |
| Sub-total | 39,197 | 4,761 | 46 | 41,251 | 0.2 | 253 | 45 | 0.5 | 8,287 | 20 | 31 | 128 |
| Corporate asset sub-class |  |  |  |  |  |  |  |  |  |  |  |  |
| 0.00 to < 0.15 | 4,357 | 1,752 | 36 | 4,953 | 0.1 | 26 | 43 | 2.2 | 1,015 | 20 | 1 |  |
| 0.15 to $<0.25$ | 4,250 | 4,183 | 31 | 6,002 | 0.2 | 102 | 44 | 2.2 | 2,486 | 41 | 5 |  |
| 0.25 to $<0.50$ | 11,597 | 20,041 | 21 | 20,260 | 0.4 | 499 | 44 | 2.1 | 12,176 | 60 | 34 |  |
| 0.50 to $<0.75$ | 5,699 | 11,102 | 20 | 8,686 | 0.5 | 389 | 36 | 1.9 | 4,753 | 55 | 16 |  |
| 0.75 to <2.50 | 18,162 | 29,646 | 14 | 23,313 | 1.2 | 1,657 | 42 | 1.4 | 19,347 | 83 | 120 |  |
| 2.50 to < 10.00 | 9,221 | 8,549 | 25 | 6,474 | 5.1 | 755 | 39 | 1.7 | 8,233 | 127 | 128 |  |
| 10.00 to <100.00 | 2,309 | 2,446 | 34 | 1,576 | 18.6 | 435 | 25 | 1.7 | 2,075 | 132 | 74 |  |
| 100.00 (Default) | 904 | 268 | 8 | 925 | 100.0 | 118 | 43 | 1.4 | - | - | 399 |  |
| Sub-total | 56,500 | 77,985 | 20 | 72,189 | 2.7 | 3,981 | 42 | 1.8 | 50,086 | 69 | 778 | 1,191 |

## 冊UOB

9 IRBA - CREDIT RISK EXPOSURES BY PORTFOLIO AND PD RANGE (cont'd)

|  | (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | (k) | (I) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PD range | Original on- balance sheet gross exposures $\$ \mathrm{~m}$ | Offbalance sheet exposures pre-CCF \$m | Average CCF \% | EAD <br> post-CRM and post-CCF \$m | Average PD \% | Number of Obligors | Average LGD \% | Average Maturity Years | $\begin{aligned} & \text { RWA } \\ & \$ \mathrm{~m} \end{aligned}$ | RWA density \% | $\begin{aligned} & \text { EL } \\ & \$ \mathrm{~m} \end{aligned}$ | $\begin{array}{r} \text { TEP } \\ \$ \mathrm{~m} \end{array}$ |


| Corporate small business asset sub-class |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.00 to < 0.15 | - | 4 | 11 | 0 | 0.1 | 2 | 11 | 1.0 | 0 | 3 | 0 |  |
| 0.15 to $<0.25$ | 81 | 738 | 13 | 223 | 0.2 | 196 | 35 | 1.7 | 58 | 26 | 0 |  |
| 0.25 to $<0.50$ | 803 | 2,224 | 9 | 1,226 | 0.4 | 585 | 37 | 2.0 | 511 | 42 | 2 |  |
| 0.50 to $<0.75$ | 1,129 | 1,958 | 9 | 1,347 | 0.5 | 543 | 37 | 2.3 | 718 | 53 | 3 |  |
| 0.75 to < 2.50 | 6,075 | 7,617 | 12 | 7,284 | 1.4 | 2,833 | 39 | 2.0 | 5,532 | 76 | 39 |  |
| 2.50 to < 10.00 | 4,988 | 4,512 | 12 | 4,889 | 5.1 | 2,191 | 37 | 1.7 | 5,096 | 104 | 93 |  |
| 10.00 to <100.00 | 1,074 | 616 | 22 | 1,007 | 16.9 | 494 | 39 | 1.6 | 1,659 | 165 | 65 |  |
| 100.00 (Default) | 655 | 233 | 2 | 660 | 100.0 | 169 | 42 | 1.1 | - | - | 278 |  |
| Sub-total | 14,804 | 17,902 | 12 | 16,636 | 7.2 | 7,013 | 38 | 1.9 | 13,574 | 82 | 479 | 552 |

Specialised lending asset sub-class - IPRE


Equities exposures under IRBA (EQ) - PD/LGD method

| 0.00 to < 0.15 | 9 | - | - | 9 | 0.0 | 1 | 90 | 5.0 | 11 | 130 | 0 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.15 to $<0.25$ | - | - | - | - | - | - | - | - | - | - | - |  |
| 0.25 to $<0.50$ | - | - | - | - | - | - | - | - | - | - | - |  |
| 0.50 to $<0.75$ | - | - | - | - | - | - | - | - | - | - | - |  |
| 0.75 to $<2.50$ | - | - | - | - | - | - | - | - | - | - | - |  |
| 2.50 to < 10.00 | - | - | - | - | - | - | - | - | - | - | - |  |
| 10.00 to $<100.00$ | - | - | - | - | - | - | - | - | - | - | - |  |
| 100.00 (Default) | - | - | - | - | - | - | - | - | - | - | - |  |
| Sub-total | 9 | - | - | 9 | 0.0 | 1 | 90 | 5.0 | 11 | 130 | 0 | 0 |
| Total (FIRB portfolios) | 188,152 | 112,401 | 24 | 214,623 | 1.8 | 13,378 | 43 | 1.6 | 112,724 | 53 | 1,564 | 2,504 |

## 冊UOB

9 IRBA - CREDIT RISK ExpOSURES BY PORTFOLIO AND PD RANGE (cont'd)

|  | (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | (k) | (1) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PD range | Original onbalance sheet gross exposures \$m | Off- <br> balance sheet exposures pre-CCF \$m | Average CCF \% | EAD <br> post-CRM and post-CCF \$m | Average PD \% | Number of Obligors | Average LGD \% | Average Maturity Years | RWA \$m | RWA density \% | $\begin{aligned} & \text { EL } \\ & \$ \mathrm{~m} \end{aligned}$ | $\begin{array}{r} \text { TEP } \\ \$ \mathrm{~m} \\ \hline \end{array}$ |


| 0.00 to < 0.15 | 544 | 261 | 104 | 815 | 0.1 | 15,814 | 20 | - | 31 | 4 | 0 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.15 to $<0.25$ | 2,165 | 3 | 39 | 2,166 | 0.2 | 22,239 | 35 | - | 298 | 14 | 1 |  |
| 0.25 to $<0.50$ | 44,625 | 3,791 | 75 | 47,462 | 0.4 | 105,584 | 11 | - | 3,404 | 7 | 19 |  |
| 0.50 to $<0.75$ | 2,573 | 27 | 40 | 2,584 | 0.5 | 24,471 | 31 | - | 674 | 26 | 4 |  |
| 0.75 to $<2.50$ | 11,715 | 899 | 67 | 12,321 | 1.5 | 46,999 | 11 | - | 2,422 | 20 | 21 |  |
| 2.50 to $<10.00$ | 4,765 | 200 | 59 | 4,884 | 5.4 | 20,145 | 14 | - | 2,383 | 49 | 36 |  |
| 10.00 to <100.00 | 1,829 | 26 | 49 | 1,842 | 24.6 | 8,144 | 17 | - | 1,746 | 95 | 72 |  |
| 100.00 (Default) | 700 | 1 | - | 700 | 100.0 | 2,873 | 21 | - | 654 | 93 | 111 |  |
| Sub-total | 68,916 | 5,207 | 74 | 72,774 | 2.5 | 224,579 | 13 | - | 11,613 | 16 | 265 | 290 |


| 0.00 to < 0.15 | 825 | 5,057 | 29 | 2,317 | 0.1 | 530,822 | 52 | - | 83 | 4 | 1 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.15 to $<0.25$ | 2 | 11 | 19 | 4 | 0.2 | 13,546 | 50 | - | 0 | 6 | 0 |  |
| 0.25 to $<0.50$ | 502 | 5,311 | 64 | 3,905 | 0.3 | 832,567 | 51 | - | 306 | 8 | 6 |  |
| 0.50 to $<0.75$ | 443 | 1,039 | 57 | 1,032 | 0.7 | 264,685 | 55 | - | 172 | 17 | 4 |  |
| 0.75 to < 2.50 | 751 | 2,047 | 79 | 2,366 | 1.4 | 327,962 | 39 | - | 506 | 21 | 14 |  |
| 2.50 to $<10.00$ | 617 | 515 | 73 | 994 | 5.3 | 222,260 | 57 | - | 751 | 76 | 30 |  |
| 10.00 to <100.00 | 431 | 88 | 71 | 494 | 26.0 | 119,405 | 69 | - | 865 | 175 | 86 |  |
| 100.00 (Default) | 45 | - | - | 45 | 100.0 | 10,549 | 69 | - | 87 | 192 | 25 |  |
| Sub-total | 3,617 | 14,069 | 54 | 11,157 | 2.5 | 1,966,954 | 50 | - | 2,769 | 25 | 166 | 68 |


| Other retail exposures asset sub-class (excluding exposures to small business) |
| :--- | :--- | :--- | :--- |
| 0 |


| Other retail exposures asset sub-class (excluding exposures to small business) |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.00 to < 0.15 | 66 | 251 | 38 | 163 | 0.1 | 3,164 | 37 | - | 16 | 10 | 0 |  |
| 0.15 to $<0.25$ | 1,058 | 0 | - | 1,058 | 0.2 | 25,605 | 11 | - | 46 | 4 | 0 |  |
| 0.25 to $<0.50$ | 34 | 178 | 55 | 132 | 0.3 | 1,330 | 28 | - | 21 | 16 | 0 |  |
| 0.50 to $<0.75$ | 5,146 | 845 | 46 | 5,536 | 0.6 | 21,682 | 10 | - | 440 | 8 | 3 |  |
| 0.75 to < 2.50 | 2,445 | 771 | 75 | 3,025 | 1.7 | 27,344 | 7 | - | 266 | 9 | 3 |  |
| 2.50 to < 10.00 | 780 | 125 | 59 | 854 | 5.8 | 49,303 | 30 | - | 407 | 48 | 15 |  |
| 10.00 to <100.00 | 460 | 8 | 68 | 465 | 23.6 | 59,613 | 48 | - | 516 | 111 | 50 |  |
| 100.00 (Default) | 99 | 0 | - | 99 | 100.0 | 5,129 | 51 | - | 473 | 478 | 17 |  |
| Sub-total | 10,088 | 2,178 | 57 | 11,331 | 3.0 | 189,914 | 13 | - | 2,184 | 19 | 89 | 52 |

## 冊 UOB



| 0.00 to < 0.15 | 16 | 75 | 69 | 68 | 0.1 | 382 | 8 | - | 1 | 1 | 0 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.15 to $<0.25$ | 467 | 665 | 68 | 921 | 0.2 | 3,651 | 20 | - | 77 | 8 | 0 |  |
| 0.25 to $<0.50$ | 2,025 | 950 | 61 | 2,603 | 0.4 | 9,615 | 25 | - | 411 | 16 | 2 |  |
| 0.50 to $<0.75$ | 925 | 336 | 56 | 1,113 | 0.5 | 4,889 | 26 | - | 225 | 20 | 2 |  |
| 0.75 to < 2.50 | 3,010 | 923 | 47 | 3,446 | 1.3 | 14,504 | 28 | - | 1,097 | 32 | 12 |  |
| 2.50 to < 10.00 | 1,106 | 198 | 46 | 1,197 | 4.6 | 5,664 | 29 | - | 529 | 44 | 16 |  |
| 10.00 to <100.00 | 270 | 20 | 50 | 280 | 21.5 | 1,256 | 26 | - | 171 | 61 | 15 |  |
| 100.00 (Default) | 166 | 17 | 4 | 167 | 100.0 | 768 | 42 | - | 338 | 202 | 53 |  |
| Sub-total | 7,985 | 3,185 | 57 | 9,795 | 3.5 | 40,727 | 26 | - | 2,850 | 29 | 100 | 97 |
| Total (Retail Asset Class) | 90,605 | 24,638 | 59 | 105,057 | 2.6 | 2,205,024 | 18 | - | 19,415 | 18 | 620 | 506 |

10 IRBA－Effect on RWA of Credit Derivatives used as CRM


## 册UOB

11 IRBA - Specialised Lending and Equities under the Simple Risk Weight Method


| \＄m |  | （a） | （b） | （c） | （d） | （e） | （f） |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Replacement cost | Potential future exposure | Effective EPE | $\alpha$ used for computing regulatory EAD | $\begin{array}{r} \text { EAD } \\ \text { (post-CRM) } \\ \hline \end{array}$ | RWA |
| 1 | Current Exposure Method（for derivatives） | 2，250 | 3，710 |  |  | 5，959 | 2，531 |
| 2 | CCR internal models method （for derivatives and SFTs） |  |  | － | － | － | － |
| 3 | FC（SA）（for SFTs） |  |  |  |  | － | － |
| 4 | FC（CA）（for SFTs） |  |  |  |  | 9，275 | 345 |
| 5 | VaR for SFTs |  |  |  |  | － | － |
| 6 | Total |  |  |  |  |  | 2，875 |

## 13 CVA RIsk Capital Requirements

|  |  | （a） | （b） |
| ---: | :--- | ---: | ---: |
| $\$ \mathbf{m}$ |  | EAD <br> （post－CRM） | RWA |
|  | Total portfolios subject to the Advanced CVA capital requirement | - | - |
| 1 | （i）VaR component（including the three－times multiplier） |  | - |
| 2 | （ii）Stressed VaR component（including the three－times multiplier） |  | - |
| 3 | All portfolios subject to the Standardised CVA capital requirement | 4,944 | 1,340 |
| $\mathbf{4}$ | Total portfolios subject to the CVA risk capital requirement | $\mathbf{4 , 9 4 4}$ | $\mathbf{1 , 3 4 0}$ |

## 14 Standardised Approach－CCR Exposures by Portfolio and Risk Weights

| \＄m | （a） | （b） | （c） | （d） | （e） | （f） | （g） | （h） | （i） |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Risk weight <br> Asset classes | 0\％ | 10\％ | 20\％ | 50\％ | 75\％ | 100\％ | 150\％ | Others | Total <br> Credit <br> Exposure |
| Central government and central bank | 2 | － | － | － | － | － | － | － | 2 |
| PSE | － | － | 39 | － | － | 18 | － | － | 57 |
| MDB | 5 | － | － | － | － | － | － | － | 5 |
| Bank | － | － | 35 | 9 | － | 8 | － | － | 52 |
| Corporate | － | － | 2 | 164 | － | 1，098 | － | － | 1，265 |
| Regulatory retail | － | － | － | － | 4 | － | － | － | 4 |
| Other exposures | － | － | － | － | － | 14 | － | － | 14 |
| Total | 7 | － | 76 | 173 | 4 | 1，139 | － | － | 1，399 |

## 册UOB

## 15 IRBA - CCR Exposures by Portrolio and PD Range

|  | (a) | (b) | (c) | (d) | (e) | (f) | (g) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PD range | $\begin{array}{r} \text { EAD } \\ \text { post- } \\ \text { CRM } \\ \$ \mathrm{~m} \end{array}$ | Average PD \% | Number of obligors | Average LGD \% | Average maturity Years | $\begin{array}{r} \text { RWA } \\ \$ \mathrm{~m} \\ \hline \end{array}$ | RWA density \% |
| Sovereign asset sub-class |  |  |  |  |  |  |  |
| 0.00 to < 0.15 | 2,912 | 0.0 | 5 | 8 | 0.2 | 0 | 0 |
| 0.15 to <0.25 | 8 | 0.2 | 1 | 8 | 0.0 | 0 | 4 |
| 0.25 to <0.50 | 17 | 0.4 | 1 | 8 | 0.0 | 1 | 6 |
| 0.50 to <0.75 | - | - | - | - | - | - | - |
| 0.75 to <2.50 | - | - | - | - | - | - | - |
| 2.50 to < 10.00 | - | - | - | - | - | - | - |
| 10.00 to <100.00 | 0 | 18.5 | 1 | 45 | 0.0 | 0 | 221 |
| 100.00 (Default) | - | - | - | - | - | - | - |
| Sub-total | 2,937 | 0.0 | 8 | 8 | 0.1 | 2 | 0 |
| Bank asset sub-class |  |  |  |  |  |  |  |
| 0.00 to < 0.15 | 5,731 | 0.1 | 138 | 19 | 0.5 | 399 | 7 |
| 0.15 to <0.25 | 1,177 | 0.2 | 24 | 1 | 0.1 | 8 | 1 |
| 0.25 to $<0.50$ | 662 | 0.4 | 11 | 3 | 0.1 | 19 | 3 |
| 0.50 to $<0.75$ | 10 | 0.6 | 2 | 45 | 1.0 | 8 | 77 |
| 0.75 to <2.50 | 1 | 1.3 | 2 | 45 | 0.2 | 1 | 75 |
| 2.50 to < 10.00 | 1 | 4.3 | 1 | 45 | 1.3 | 1 | 136 |
| 10.00 to <100.00 | - | - | - | - | - | - | - |
| 100.00 (Default) | - | - | - | - | - | - | - |
| Sub-total | 7,582 | 0.1 | 178 | 15 | 0.4 | 435 | 6 |
| Corporate asset sub-class |  |  |  |  |  |  |  |
| 0.00 to < 0.15 | 92 | 0.1 | 8 | 45 | 2.9 | 24 | 26 |
| 0.15 to <0.25 | 313 | 0.2 | 25 | 45 | 2.6 | 144 | 46 |
| 0.25 to <0.50 | 348 | 0.4 | 98 | 45 | 1.8 | 196 | 56 |
| 0.50 to $<0.75$ | 935 | 0.5 | 67 | 9 | 0.1 | 94 | 10 |
| 0.75 to <2.50 | 312 | 1.2 | 297 | 40 | 1.0 | 233 | 75 |
| 2.50 to < 10.00 | 110 | 4.0 | 86 | 44 | 1.1 | 139 | 126 |
| 10.00 to <100.00 | 40 | 14.1 | 32 | 45 | 0.6 | 83 | 205 |
| 100.00 (Default) | - | - | - | - | - | - | - |
| Sub-total | 2,151 | 1.0 | 613 | 29 | 1.1 | 913 | 42 |

## 冊UOB

15 IRBA－CCR ExPOSURES BY PORTFOLIO AND PD RANGE（cont＇d）

|  | （a） | （b） | （c） | （d） | （e） | （f） | （g） |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| PD range | EAD post－ CRM \＄m | Average PD \％ | Number of obligors | Average LGD \％ | Average maturity Years | $\begin{array}{r} \text { RWA } \\ \$ \mathrm{~m} \end{array}$ | RWA density \％ |
| Corporate small business asset sub－class |  |  |  |  |  |  |  |
| 0.00 to＜ 0.15 | 0 | 0.1 | 2 | 45 | 0.0 | 0 | 7 |
| 0.15 to $<0.25$ | 2 | 0.2 | 45 | 43 | 0.2 | 0 | 18 |
| 0.25 to $<0.50$ | 1 | 0.4 | 70 | 39 | 0.3 | 0 | 29 |
| 0.50 to＜0．75 | 14 | 0.5 | 63 | 45 | 0.4 | 6 | 46 |
| 0.75 to＜ 2.50 | 81 | 1.5 | 293 | 45 | 0.6 | 65 | 80 |
| 2.50 to＜ 10.00 | 22 | 3.8 | 222 | 44 | 1.5 | 22 | 104 |
| 10.00 to＜100．00 | 0 | 14.9 | 50 | 40 | 0.2 | 1 | 167 |
| 100.00 （Default） | 0 | 100.0 | 3 | 45 | 0.2 | － | － |
| Sub－total | 120 | 1.8 | 748 | 44 | 0.7 | 95 | 79 |
| Specialised lending asset sub－class－IPRE |  |  |  |  |  |  |  |
| 0.00 to＜ 0.15 | － | － | － | － | － | － | － |
| 0.15 to＜0．25 | 27 | 0.2 | 11 | 45 | 2.5 | 12 | 45 |
| 0.25 to $<0.50$ | 85 | 0.4 | 39 | 45 | 3.0 | 60 | 71 |
| 0.50 to $<0.75$ | 5 | 0.5 | 6 | 45 | 2.2 | 3 | 72 |
| 0.75 to＜ 2.50 | 17 | 1.0 | 21 | 45 | 2.5 | 17 | 98 |
| 2.50 to＜ 10.00 | 19 | 3.3 | 2 | 45 | 4.6 | 31 | 166 |
| 10.00 to＜100．00 | 0 | 20.5 | 1 | 45 | 2.6 | 0 | 255 |
| 100.00 （Default） | － | － | － | － | － | － | － |
| Sub－total | 153 | 0.8 | 80 | 45 | 3.0 | 124 | 81 |
| Total（sum of portfolios） | 12，943 | 0.3 | 1，627 | 16 | 0.5 | 1，569 | 12 |


| \$m |  | (a) | (b) |
| :---: | :---: | :---: | :---: |
|  |  | Protection bought | Protection sold |
|  | Notionals |  |  |
| 1 | Single-name credit default swaps | 248 | 237 |
| 2 | Index credit default swaps | 83 | - |
| 3 | Total return swaps | 757 | - |
| 4 | Credit options | - | - |
| 5 | Other credit derivatives | - | - |
| 6 | Total notionals | 1,087 | 237 |
|  | Fair values |  |  |
| 7 | Positive fair value (asset) | 13 | 2 |
| 8 | Negative fair value (liability) | 19 | - |

## 17 Securitisation Exposures in the Banking Book



[^3]
## 冊 UOB

18 SECURITISATION ExpOSURES IN THE BANKING BOOK AND ASSOCIATED REGULATORY CAPITAL REQUIREMENTS - UOB ACTING AS INVESTOR

|  |  | (a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | (k) | (I) | (m) | (n) | (0) | (p) | (q) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Exposure values (by risk weight bands) |  |  |  |  | Exposure values (by regulatory approach) |  |  |  | RWA (by regulatory approach) |  |  |  | Capital charge after cap |  |  |  |
| \$m |  |  |  |  |  |  |  |  | $\stackrel{10}{\omega}$ |  |  |  |  | - |  | $\begin{aligned} & \frac{\widetilde{W}}{\infty} \\ & \frac{0}{\mathbb{\infty}} \\ & \infty \\ & \underset{\sim}{\infty} \end{aligned}$ |  |  |
| 1 | Total exposures | 56 | 66 | - | - | 11 | 122 | - | - | 11 | 34 | - | - | 143 | 3 | - | - | 14 |
| 2 | Traditional securitisation | 56 | 66 | - | - | 11 | 122 | - | - | 11 | 34 | - | - | 143 | 3 | - | - | 14 |
| 3 | of which: securitisation | 56 | 66 | - | - | 11 | 122 | - | - | 11 | 34 | - | - | 143 | 3 | - | - | 14 |
| 4 | of which: retail underlying | 27 | 66 | - | - | 11 | 93 | - | - | 11 | 30 | - | - | 143 | 3 | - | - | 14 |
| 5 | of which: wholesale | 29 | - | - | - | - | 29 | - | - | - | 4 | - | - | - | 0 | - | - | - |
| 6 | of which: resecuritisation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 7 | of which: senior | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 8 | of which: nonsenior | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 9 | Synthetic securitisation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 10 | of which: securitisation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 11 | of which: retail underlying | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 12 | of which: wholesale | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 13 | of which resecuritisation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 14 | of which: senior | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 15 | of which: nonsenior | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |


| $\$ \mathbf{m}$ |  | （a） |
| ---: | :--- | ---: |
|  | RWA |  |
|  | Products excluding options |  |
| 1 | Interest rate risk（general and specific） | 6,908 |
| 2 | Equity risk（general and specific） | 304 |
| 3 | Foreign exchange risk | 11,151 |
| 4 | Commodity risk | 543 |
|  | Options | - |
| 5 | Simplified approach | 405 |
| 6 | Delta－plus method | 61 |
| 7 | Scenario approach | - |
| $\mathbf{8}$ | Securitisation | $\mathbf{1 9 , 3 7 1}$ |
| $\mathbf{9}$ | Total |  |

## Standardised Approach

The Group currently adopts the SA for the calculation of regulatory market risk capital but uses the Internal Models Approach to measure and to control trading market risks. The financial products which are warehoused, measured and controlled with internal models include FX and FX options, plain vanilla interest rate contracts and interest rate options, government and corporate bonds, equities and equity options, commodities contracts and commodity options.

## Internal Model Approach

The Group estimates a daily Value-at-Risk (VaR) within a 99 per cent confidence interval, using the historical simulation method, as a control for market risk. The method assumes that possible future changes in market rates may be implied by observed historical market movements.

## Group Trading Backtesting Chart

(Hypothetical daily profit and loss versus VaR at 99\% confidence interval)


As VaR is the statistical measure for potential losses, the VaR measures are backtested against profit and loss of the trading book to validate the robustness of the methodology. The backtesting process analyses whether the exceptions are due to model deficiencies or market volatility. All backtesting exceptions are tabled at the ALCO with recommended actions and resolutions.

To complement the VaR measure, we perform stress and scenario tests to identify the Group's vulnerability to event risk. These tests serve to provide early warnings of plausible extreme losses for which proactive management of market risk is taken.

The Group's daily VaR on 30 June 2017 was $\$ 7.36$ million.

$\square$ Interest rate
$\square$ Foreign exchange
$\square$ Equity
Commodity
$\square$ Specific risk

## 21 Banking Book Interest Rate Risk

Interest rate risk is the impact to earnings and economic value of the Group due to fluctuations in interest rates．Interest rate exposure arises from differences in the maturity and repricing dates of assets，liabilities and off－balance sheet items． These mismatches are actively monitored and managed as part of the overall interest rate risk management process which is conducted in accordance with the Group＇s policies as approved by the ALCO．

The economic value of equity（＂EVE＂）sensitivity at 100 and 200 basis points parallel interest rate shocks were negative $\$ 257$ million and $\$ 353$ million respectively，computed based on the worst case of upward and downward parallel shifts of each yield curve．EVE is the present value of assets less present value of liabilities of the Group．The repricing profile of loans is generally based on the earliest possible repricing dates，taking into account the notice period to be served to the customers．Loan prepayment is estimated based on past statistics and trends where possible and material．Behavioural assumptions based on historical trends are applied where appropriate，for deposits that do not have maturity dates．There may be some differences in the assumptions across geographical locations due to variation in local conditions．

## 22 Summary of Disclosure Excluded

| Disclosures Description | Rationale |
| :--- | :--- |
| RWA flow statements of under CCR internal models method | UOB not using CCR Internal Models <br> Method |
| Securitisation exposures in the Trading book | Currently，UOB has no such <br> exposures in the Trading book． |
| Securitisation exposures in the Banking book and associated regulatory capital <br> requirements－A reporting bank acting as originator or as sponsor | Currently，UOB has no such <br> exposures． |
| RWA flow statements of market risk exposures under IMA | UOB not using IMA for market risk |
| IMA values for trading portfolios | UOB not using IMA for market risk |

## 23 Abbreviations

The following abbreviated terms are used throughout this document．

A

| A－IRBA | Advanced Internal Ratings－Based Approach |
| :--- | :--- |
| ALCO | Asset and Liability Committee |
| AMA | Advanced Measurement Approach |
| AT1 capital | Additional Tier 1 capital |
| B |  |


| BIA | Basic Indicator Approach |
| :--- | :--- |
| C |  |


| CAR | Capital Adequacy Ratio |
| :--- | :--- |


| CCF | Credit Conversion Factor |
| :--- | :--- |
| CCP | Central Counterparty |


| CCR | Counterparty Credit Risk |
| :--- | :--- |
| CCyB | Countercyclical Buffer |
| CET1 | Common Equity Tier 1 |
| CF | Commodities Finance |
| CR | Credit Risk |
| CRE | Commercial Real Estate |
| CRM | Credit Risk Mitigation |
| CVA | Credit Valuation Adjustment |


| E |  |
| :--- | :--- |
| EAD | Exposure at Default |
| EL | Expected Loss |
| EPE | Expected Positive Exposure |
| EQ | Equity Exposures |
| EVE | Economic Value of Equity |

F

| FC（SA） | Financial Collateral Simple Approach |
| :--- | :--- |
| FC（CA） | Financial Collateral Comprehensive <br> Approach |
| F－IRBA | Foundation Internal Ratings－Based <br> Approach |

G

| G－SIB | Global Systemically Important Bank |
| :--- | :--- |
| H |  |
| HVCRE | High－Volatility Commercial Real Estate |
| IAM | Internal Assessment Method |
| IMA | Internal Models Approach |
| IMM | Internal Models Method |
| IPRE | Income－Producing Real Estate |
| IRBA | Internal Ratings－Based Approach |
| L |  |
| LGD | Loss Given Default |
| $\mathbf{M}$ | Multilateral Development Bank |
| MDB | Market Risk |
| MR | Non－Controlling Interests |
| $\mathbf{N}$ |  |
| $\mathbf{N C I}$ |  |

0

| OF | Object Finance |
| :---: | :--- |
| OR | Operational Risk |

P

| PD | Probability of Default |
| :--- | :--- |
| PE／VC | Private Equity／Venture Capital |
| PF | Project Finance |
| PSE | Public Sector Entity |
| $\mathbf{Q}$ |  |

Q
QRRE Qualifying Revolving Retail Exposures

| RBM | Ratings－Based Method |
| :---: | :---: |
| RW | Risk Weight |
| RWA | Risk－Weighted Assets |
| S |  |
| SA | Standardised Approach |
| SA（CR） | Standardised Approach to Credit Risk |
| SA（EQ） | Standardised Approach for Equity Exposures |
| SA（SE） | Standardised Approach for Securitisation Exposures |
| SA（MR） | Standardised Approach to Market Risk |
| SA（OR） | Standardised Approach to Operational Risk |
| SE | Securitisation Exposures |
| SF | Ship Finance |
| SFTs | Securities Financing Transactions |
| T |  |
| T1 capital | Tier 1 capital |
| T2 capital | Tier 2 capital |
| TEP | Total Eligible Provisions |
| V |  |
| VaR | Value at Risk |


[^0]:    Notes：
    1 The pillar 3 disclosure report are presented in Singapore dollars．
    2 Certain figures in this report may not add up to the respective totals due to rounding．
    3 Amounts less than $\$ 500,000$ in absolute term are shown as＂ 0 ＂．

[^1]:    ${ }^{1}$ Note: This includes the Bank's major stake investments in financial institutions.

[^2]:    \# These elements are subject to a more conservative definition relative to those set out under the Basel III capital standards.

[^3]:    \# Note: The group does not have any securitisation exposures where it acts as sponsor or originator.

